[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …
…, M Fuskova, D Gbesemete, C Green, B Hallis, MM Hou… - The Lancet, 2020 - thelancet.com
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …
death if they develop COVID-19 and are therefore a priority for immunisation should an …
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 …
…, PT Heath, H Hill, K Hillson, B Horsington, MM Hou… - The Lancet, 2021 - thelancet.com
Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …
immunity in some countries as the interval between the first and second dose becomes …
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection
MM Hou, JR Barrett, Y Themistocleous… - Science translational …, 2023 - science.org
There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a
clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII)…
clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII)…
[HTML][HTML] Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly
…, A Marini, M Zaric, M Mulatier, RL Ramon, M Baker… - JCI insight, 2021 - ncbi.nlm.nih.gov
Controlled human malaria infection (CHMI) provides a highly informative means to investigate
host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of new …
host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of new …
[HTML][HTML] Impact of a blood-stage vaccine on Plasmodium vivax malaria
MM Hou, JR Barrett, Y Themistocleous, TA Rawlinson… - MedRxiv, 2022 - ncbi.nlm.nih.gov
Background: There are no licensed vaccines against Plasmodium vivax, the most common
cause of malaria outside of Africa. Methods: We conducted two Phase I/IIa clinical trials to …
cause of malaria outside of Africa. Methods: We conducted two Phase I/IIa clinical trials to …
Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage …
…, CG Mkindi, KM Kwiatkowska, MM Hou… - Frontiers in …, 2024 - frontiersin.org
We have previously reported primary endpoints of a clinical trial testing two vaccine platforms
for the delivery of Plasmodium vivax malaria DBPRII: viral vectors (ChAd63, MVA), and …
for the delivery of Plasmodium vivax malaria DBPRII: viral vectors (ChAd63, MVA), and …
PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial
FJ Martinez, M White, M Guillotte-Blisnick, C Huon… - npj Vaccines, 2024 - nature.com
The receptor-binding domain, region II, of the Plasmodium vivax Duffy binding protein (PvDBPII)
binds the Duffy antigen on the reticulocyte surface to mediate invasion. A heterologous …
binds the Duffy antigen on the reticulocyte surface to mediate invasion. A heterologous …
PvDBPII-Matrix M elicits polyfunctional antibodies that limit parasite growth in a challenge trial
FJ Martinez, M White, M Guillotte-Blisnick, C Huon… - medRxiv, 2023 - medrxiv.org
The receptor-binding domain, region II, of Plasmodium vivax Duffy binding protein (PvDBPII)
binds the Duffy antigen on reticulocytes to mediate invasion. A heterologous vaccine …
binds the Duffy antigen on reticulocytes to mediate invasion. A heterologous vaccine …
First Phase 1b, single-center, age de-escalation trial of the P. falciparum blood-stage malaria vaccine candidate RH5.1/Matrix-M™: a delayed boost regimen induces …
…, JJ Kamage, JR Barrett, LDW King, MM Hou… - medRxiv, 2024 - medrxiv.org
Background RH5.1 is a soluble protein vaccine candidate for blood-stage Plasmodium
falciparum malaria, previously trialed in healthy UK adults in combination with AS01 B adjuvant. …
falciparum malaria, previously trialed in healthy UK adults in combination with AS01 B adjuvant. …
Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics
…, TA Rawlinson, RO Payne, MM Hou… - Frontiers in …, 2022 - frontiersin.org
In endemic settings it is known that natural malaria immunity is gradually acquired following
repeated exposures. Here we sought to assess whether similar acquisition of blood-stage …
repeated exposures. Here we sought to assess whether similar acquisition of blood-stage …
